Luis Diaz, MD, is the Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center in New York. Dr. Diaz led the landmark study of PD-1 blockade in MSI CRC, the first successful trial of immunotherapy in CRC, which has led to pembrolizumab receiving FDA breakthrough designation in treatment-refractory colorectal cancer with mismatch repair deficiency. He also has pioneered the use of circulating tumor DNA as a means of early detection of tumor recurrence and a strategy for monitoring emergence of therapeutic resistance in the blood (as a co-discoverer of KRAS mutations as an acquired resistance mechanism to anti-EGFR antibodies in CRC).
He was formerly an associate professor of oncology at Johns Hopkins Medicine.
Dr. Diaz obtained his bachelor’s degree in microbiology at the University of Michigan and his MD at the University of Michigan Medical School.